This report was first published by Endpoints News. To see the original version, click here
Bristol Myers Squibb is facing a bit of an identity crisis.
CEO Chris Boerner is nearly two and a half years into his tenure, with most of his time defined by stringent cost-cutting. In the aftermath of the massive, $74 billion Celgene acquisition, the cuts have positioned Bristol Myers as a more “agile” company with a slate of pipeline readouts coming this year that has drawn excitement from Wall Street.
您已阅读7%（497字），剩余93%（6171字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。